Schoenefeld E, Donas K, Radicke A, Osada N, Austermann M, Torsello G
Department of Vascular Surgery, St. Franziskus Hospital Muenster, and Centre of Vascular and Endovascular Surgery, CVEC, Muenster University Hospital, Muenster, Germany.
Vasa. 2012 Jul;41(4):282-7. doi: 10.1024/0301-1526/a000204.
This study was initiated to evaluate the cardiovascular benefit of perioperative use of acetylsalicylic acid (ASA) in patients undergoing carotid surgery.
A prospective two-arm comparative study was conducted and focused on cardiac, neurological and bleeding complications for patients with high-grade (> 80 %) asymptomatic or symptomatic (> 60 %), internal carotid artery stenosis based on NASCET criteria who were treated by surgery. Between March 2008 and November 2010, 540 patients underwent carotid endarterectomy in two European vascular centers. In particular, 267 consecutive patients (49.4 %) had taken perioperative ASA in one center; in 273 consecutive patients in the other center ASA administration was stopped 5 days preoperatively.
The overall complication rate was lower in the ASA group (5.2 % versus 17.6 %), p < 0.001, 95 %CI [2.1;7.2], OR 3.8. In detail, the myocardial event rate was lower in the ASA arm: 0.7 versus 4.4 %; p = 0.012, OR 6.1 (95 %CI [1.4;27.45]. Concerning stroke, ASA patients benefit from oral antiaggregation as well: 1.5 vs. 5.5 %; p = 0.036), OR 4.5, 95 %CI[1.3;11.7], respectively. The bleeding complications were similar in both subgroups, 8 for the ASA group (3.0 %) and 10 (3.7 %) for the non-ASA group, p = 0.66. Multivariate logistic regression analysis showed significant benefit of the ASA-treatment in patients with hypertension, diabetes mellitus and hypercholesterolemia, p < 0.001. Additionally, female patients of the ASA group also had significantly less overall (p = 0.10, OR5.3), cardiac (p = 0.021, OR 3.6) and neurologic (p = 0.042, OR 6.7) complications. Bleeding risk was not higher in female patients receiving ASA (p = 0.25).
Perioperative use of ASA for patients undergoing carotid endarterectomy is associated with a lower risk of cardiac and neurological events without significant increase of postoperative bleeding necessitating revision.
本研究旨在评估围手术期使用乙酰水杨酸(ASA)对接受颈动脉手术患者的心血管益处。
进行了一项前瞻性双臂对照研究,重点关注根据北美症状性颈动脉内膜切除术试验(NASCET)标准,患有高级别(>80%)无症状或症状性(>60%)颈内动脉狭窄并接受手术治疗的患者的心脏、神经和出血并发症。2008年3月至2010年11月期间,540例患者在两个欧洲血管中心接受了颈动脉内膜切除术。具体而言,在一个中心,267例连续患者(49.4%)围手术期服用了ASA;在另一个中心的273例连续患者中,术前5天停用了ASA。
ASA组的总体并发症发生率较低(5.2%对17.6%),p<0.001,95%置信区间[2.1;7.2],比值比(OR)为3.8。详细来说,ASA组的心肌事件发生率较低:0.7%对4.4%;p=0.012,OR为6.1(95%置信区间[1.4;27.45])。关于中风,服用ASA的患者也从口服抗聚集药物中获益:分别为1.5%对5.5%;p=0.036),OR为4.5,95%置信区间[1.3;11.7]。两个亚组的出血并发症相似,ASA组有8例(3.0%),非ASA组有10例(3.7%),p=0.66。多因素逻辑回归分析显示,ASA治疗对高血压、糖尿病和高胆固醇血症患者有显著益处,p<0.001。此外,ASA组的女性患者总体并发症(p=0.10,OR5.3)、心脏并发症(p=0.021,OR3.6)和神经并发症(p=0.042,OR6.7)也明显较少。接受ASA治疗的女性患者出血风险并未更高(p=0.25)。
颈动脉内膜切除术患者围手术期使用ASA与心脏和神经事件风险降低相关,且术后出血需要再次手术的情况无显著增加。